Biotech Sell-Off Resumes-Another Test For April 15 Bottom.. Update-2.. 4/29

http://ipjornal.com/tema/noticias-financeiras Biotech Sector Perking Up in Active Trading 2:15 P Tuesday

Key tracking indices: best place to buy accutane online uk NASDAQ 4107 up 0.83%, http://rabisingoznuru.com/tag/satici/ IBB  229.2 up 2.75%,   XBI 128.40 up 3.9%, XLV $58 up 0.55%.

Rayno Biopharma Portfolio Movers Up: ABBVALKS, ALXN,BIIB, CBST,  GILD, PCYC, SGEN etc

Rayno Dx and Tools Portfolio Movers Up: LMNX, HOLX, NSTG, SQNM: Down- ALR, EXAS, RGDX

Still a trader’s market but holding core positions. Cash at 30% in life science portfolios. April 15 bottom technicals holding.

————

April 15 Bottom Holding in Mixed Trading: IBB at $225, XBI at $124

Rayno Portfolio upside movers: ABAX, ABBV, ALKS, GILD, PCYC, SQNM

Major ETFs Get Hit Again: Steady Sell-Off of XBI ($124) Since Tuesday’s High

NASDAQ Down 1.8% as High Flying AMZN and NFLX get crushed

The institutions who created the 2014 bio-bubble are going to cash. Momentum  is gone from the market as investors move from speculation to quality and value. The XBI ETF holds the most speculative biopharmaceutical stocks and it is in “free-fall” approaching its April 15 lows of $115. The next technical signal would be a double bottom.

We recommended a 30% cash position in life science portfolios as the early April sell-off commenced and new buys are to be avoided .

, ,

No comments yet.

Leave a Reply